Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

Articles citing Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

Title / Author	Year
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations W Zou, JD Wolchok, L Chen Science translational medicine 8 (328), 328rv4-328rv4	2016
PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome HO Alsaab, S Sau, R Alzhrani, K Tatiparti, K Bhise, SK Kashaw, AK Iyer Frontiers in pharmacology 8, 561	2017
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response G Chen, AC Huang, W Zhang, G Zhang, M Wu, W Xu, Z Yu, J Yang, ... Nature 560 (7718), 382-386	2018
Targeting neoantigens to augment antitumour immunity M Yarchoan, BA Johnson III, ER Lutz, DA Laheru, EM Jaffee Nature Reviews Cancer 17 (4), 209	2017
Cancer immunotherapy: harnessing the immune system to battle cancer Y Yang The Journal of clinical investigation 125 (9), 3335-3337	2015
Radiotherapy and immunotherapy: a beneficial liaison? RR Weichselbaum, H Liang, L Deng, YX Fu Nature reviews Clinical oncology 14 (6), 365	2017
A paradigm shift in cancer immunotherapy: from enhancement to normalization MF Sanmamed, L Chen Cell 175 (2), 313-326	2018
Resistance to PD1/PDL1 checkpoint inhibition JS O'Donnell, GV Long, RA Scolyer, MWL Teng, MJ Smyth Cancer treatment reviews 52, 71-81	2017
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues J Hamanishi, M Mandai, N Matsumura, K Abiko, T Baba, I Konishi International journal of clinical oncology 21 (3), 462-473	2016
In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy C Wang, W Sun, Y Ye, Q Hu, HN Bomba, Z Gu Nature Biomedical Engineering 1 (2), 1-10	2017
Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients M Ilie, V Hofman, M Dietel, JC Soria, P Hofman Virchows Archiv 468 (5), 511-525	2016
PD-1 and PD-L1 antibodies in cancer: current status and future directions AV Balar, JS Weber Cancer Immunology, Immunotherapy 66 (5), 551-564	2017
IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer TA Mace, R Shakya, JR Pitarresi, B Swanson, CW McQuinn, S Loftus, ... Gut 67 (2), 320-332	2018
Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer PE Hughes, S Caenepeel, LC Wu Trends in immunology 37 (7), 462-476	2016
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial CR Heery, G O'Sullivan-Coyne, RA Madan, L Cordes, A Rajan, ... The Lancet Oncology 18 (5), 587-598	2017
PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression H Tang, Y Liang, RA Anders, JM Taube, X Qiu, A Mulgaonkar, X Liu, ... The Journal of clinical investigation 128 (2), 580-588	2018
COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells V Prima, LN Kaliberova, S Kaliberov, DT Curiel, S Kusmartsev Proceedings of the National Academy of Sciences 114 (5), 1117-1122	2017
Immune targets and neoantigens for cancer immunotherapy and precision medicine RF Wang, HY Wang Cell research 27 (1), 11-37	2017
Tailoring biomaterials for cancer immunotherapy: Emerging trends and future outlook C Wang, Y Ye, Q Hu, A Bellotti, Z Gu Advanced materials 29 (29), 1606036	2017
Enhancing CD8+ T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy Y Zhang, R Kurupati, L Liu, XY Zhou, G Zhang, A Hudaihed, F Filisio, ... Cancer Cell 32 (3), 377-391. e9	2017

1 - 20

Dates and citation counts are estimated and are determined automatically by a computer program.